Patents by Inventor Sandrine Pierre

Sandrine Pierre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treatment and diagnosis of non-alcoholic steatohepatitis and/or hepatocellular carcinoma
    Patent number: 11958915
    Abstract: Methods for treating non-alcoholic steatohepatitis and/or hepatocellular carcinoma include administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof. Methods and assays for diagnosis or prognosis of non-alcoholic steatohepatitis and/or hepatocellular carcinoma in a subject are also provided and include the steps of providing a biological sample from the subject, determining an expression level or activity in the sample of at least one biomarker selected from Caveolin-1, Survivin, and SMAC; and comparing the expression level or activity of the at least one biomarker in the sample, if present, to a control expression level or activity of the at least one biomarker. Prophylaxis or treatment of the non-alcoholic steatohepatitis and/or hepatocellular carcinoma in a subject can then be initiated based on the expression level or activity of Caveolin-1, Survivin, and SMAC in the sample.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: April 16, 2024
    Assignee: MARSHALL UNIVERSITY RESEARCH CORPORATION
    Inventors: Juan Sanabria, Sandrine Pierre, Moumita Banerjee, Zijian Xie, Joseph Shapiro
  • METHODS FOR TREATMENT AND DIAGNOSIS OF NON-ALCOHOLIC STEATOHEPATITIS AND/OR HEPATOCELLULAR CARCINOMA
    Publication number: 20210309698
    Abstract: Methods for treating non-alcoholic steatohepatitis and/or hepatocellular carcinoma include administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof. Methods and assays for diagnosis or prognosis of non-alcoholic steatohepatitis and/or hepatocellular carcinoma in a subject are also provided and include the steps of providing a biological sample from the subject, determining an expression level or activity in the sample of at least one biomarker selected from Caveolin-1, Survivin, and SMAC; and comparing the expression level or activity of the at least one biomarker in the sample, if present, to a control expression level or activity of the at least one biomarker. Prophylaxis or treatment of the non-alcoholic steatohepatitis and/or hepatocellular carcinoma in a subject can then be initiated based on the expression level or activity of Caveolin-1, Survivin, and SMAC in the sample.
    Type: Application
    Filed: April 6, 2021
    Publication date: October 7, 2021
    Inventors: Juan Sanabria, Sandrine Pierre, Moumita Banerjee, Zijian Xie, Joseph Shapiro